Addendum to guidelines on the investigation and management of venous thrombosis at unusual sites: Use of Direct Oral Anticoagulants

Addendum to guidelines on the investigation and management of venous thrombosis at unusual sites (Br. J. Haematol. 2012;159:28–38): Use of Direct Oral Anticoagulants - British Society for Haematology (BSH)

Currently Direct Oral Anticoagulants (DOACs) are licensed for treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) whereas warfarin is licensed for all venous thrombosis (VTE). Warfarin, with low-molecular-weight hep-arin (LMWH) during the acute initial phase, is therefore the standard agent for long-term anticoagulation for patients with thrombosis at other sites. The large phase 3, randomised, con-trolled trials comparing the DOACs: dabigatran, rivaroxaban, apixaban and edoxaban with warfarin in DVT and PE patients, did not include those with thrombosis at unusual sites.


Read full guideline